Reimagining cancer research and its implementation in Europe—an unrivalled opportunity

Key findings from the Lancet Oncology European Groundshot Commission on cancer research include...

Cancer research is booming in western Europe, but is stagnant in eastern Europe

Number of cancer research papers published...

<table>
<thead>
<tr>
<th>Year</th>
<th>Predominantly western European</th>
<th>Predominantly eastern European</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>20,000 papers</td>
<td>0 papers</td>
</tr>
<tr>
<td>2020</td>
<td>40,000 papers</td>
<td>0 papers</td>
</tr>
</tbody>
</table>

Lung cancer merits greater research attention than it currently receives

% of research on lung cancer, 2009-2020

% of cancer DALYs, 2015

Lung cancer 21% of disease burden
4% of research activity

The Commission makes 12 realistic recommendations for achieving impactful change

1. Double implementation science and health services research activity by 2024
2. Ensure all Europeans benefit from cancer research no matter where they live
3. Increase cancer research capacity and capability in eastern Europe by 25% by 2025
4. Double cancer research funding in Europe to 50€ per head by 2030
5. Mitigate Brexit by facilitating UK involvement in European cancer research
6. Enhance gender equality in cancer research
7. Implement research advances to eradicate HPV-driven cancers by 2030
8. Deploy comprehensive cancer centres as powerhouses for cancer research and its translation into superior clinical care
9. Establish a European Cancer Survivorship Research Plan by 2023
10. Deliver a data dashboard to capture and mitigate in real time the impact of COVID-19 on cancer by 2023
11. Ensure clinical trial activity is maintained and enhanced in central and eastern Europe despite the impact of the war in Ukraine
12. Double collaborative cancer research between Europe and low-income and middle-income countries by 2027

Read the full Lancet Oncology Commission at www.thelancet.com